Company Profile
BioCryst Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- BCRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
9.30 USD (+2.54%)
Close
Last updated: August 6, 2026
2.12B USD
Market cap
Why the stock is moving
The latest company update was “BioCryst Reports Second Quarter 2026 Financial Results”. BCRX changed 0.55% and closed at $9.07 on Aug 5, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Rare-Disease Drug Development
BioCryst Pharmaceuticals discovers, develops and commercializes small-molecule medicines for rare diseases. Its portfolio combines a marketed hereditary angioedema franchise with clinical programs targeting additional protein-mediated disorders.
ORLADEYO Commercial Franchise
ORLADEYO is an oral preventive therapy for hereditary angioedema and provides the company’s principal commercial foundation. Its once-daily oral profile differentiates it from injectable prophylactic options and supports BioCryst’s established presence in the HAE market.
Navenibart in Hereditary Angioedema
Navenibart is a long-acting investigational treatment being evaluated in the pivotal ALPHA-ORBIT study for HAE. BioCryst retains core development responsibilities while licensing European commercial rights to Neopharmed Gentili.
BCX17725 for Netherton Syndrome
BCX17725 is an investigational KLK5 inhibitor in Phase 1 development for Netherton syndrome. The program extends BioCryst’s small-molecule expertise into a rare genetic skin disorder with limited treatment options.
Future catalysts
Completion of enrollment in the pivotal ALPHA-ORBIT navenibart study expected by the end of June 2026.
Data from Part 4 of the BCX17725 Phase 1 trial expected by year-end 2026.
U.S. regulatory filing for navenibart targeted by the end of 2027.
Recent news
- 01
BioCryst Reports Second Quarter 2026 Financial Results
Source: BioCryst Pharmaceuticals
- 02
BioCryst to Report Second Quarter 2026 Financial Results on August 5
Source: BioCryst Pharmaceuticals
- 03
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
Source: BioCryst Pharmaceuticals
- 04
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: BioCryst Pharmaceuticals
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BioCryst Pharmaceuticals (BCRX)?
BioCryst Pharmaceuticals (BCRX) most recently closed at 9.30 USD, a +2.54% move versus the previous session.
What is the market cap of BioCryst Pharmaceuticals (BCRX)?
BioCryst Pharmaceuticals currently has a market capitalization of 2.12B USD on BioPharmSignal.
What does BioCryst Pharmaceuticals do?
Rare-Disease Drug Development BioCryst Pharmaceuticals discovers, develops and commercializes small-molecule medicines for rare diseases. Its portfolio combines a marketed hereditary angioedema franchise with clinical programs targeting additional protein-mediated disorders. ORLADEYO Commercial Franchise ORLADEYO is an oral preventive therapy for hereditary...
On which exchange is BCRX stock listed?
BioCryst Pharmaceuticals (BCRX) is associated with NASDAQ, United States, Biopharma.
What is ALPHA-ORBIT?
Completion of enrollment in the pivotal ALPHA-ORBIT navenibart study expected by the end of June 2026.
Which conditions is BioCryst Pharmaceuticals targeting with ALPHA-ORBIT?
BioCryst Pharmaceuticals is associated with rare disease, genetic disease based on its company overview and current catalyst commentary.
How does BioCryst Pharmaceuticals describe recent progress with ALPHA-ORBIT?
Completion of enrollment in the pivotal ALPHA-ORBIT navenibart study expected by the end of June 2026.
What is Rare-Disease?
Rare-Disease Drug Development BioCryst Pharmaceuticals discovers, develops and commercializes small-molecule medicines for rare diseases.